or over 25 years, ABR has served the global pharmaceutical and biotechnology industries with world-class testing service, careful attention to quality and industry-leading turnaround time. The team of scientists at ABR is dedicated to providing accurate, timely, and precise results, while ensuring a high degree of customer service. ABR continues to design and develop virus detection protocols and other assays to meet evolving needs and changing regulations.ABR?s virus assays satisfy United States 9th Code of Federal Regulation (9CFR), European Medicines Agency (EMA/EMEA), CVMP and CHMP (CPMP) regulations. Additionally, ABR operates under the principles of Good Laboratory Practice (GLP) as defined in the Twenty-first Code of Federal Regulations (21CFR), Part 58. In order to provide a wider service offering, ABR has recently developed assays for mycoplasma by USDA-9CFR, European Pharmacopeia (EP), United States Pharmacopeia (USP) and the FDA requirements as well as species of origin and IgG level tests. More assays and other regulatory compliance methods are under development.